Clinical trials: Influenza Type A

Influenza Type A, Influenza Type B

Safety, Tolerability, and Pharmacokinetics of SAB-176 in Healthy Participants

• Completed
• Age: 18 to 60 years
• Phase 1
• Results posted

Influenza causes substantial morbidity and mortality worldwide despite available antivirals and vaccines. SAB Biotherapeutics, Inc.

Conditions

Influenza Type A, Influenza Type B, Influenza

Trial name

NCT04471038

Testing

SAB-176, Normal Saline

Where

United States

Volunteers

27 people, healthy volunteers welcome

Sponsor

SAb Biotherapeutics, Inc.